In 2015, le Rolle and colleagues found that CXCL1 overexpression is a poor prognostic marker on metastatic CRC, furthermore, CXCL1 inhibition could suppress tumor cell growth of KRAS mutant CRC cells [58]. The gene discussed is KRAS; the disease is neoplasm.